ABERA BIOSCIENCE AB Total Liabilities
ABERA BIOSCIENCE AB total liabilities. Based on the latest financial reports, ABERA BIOSCIENCE AB (8WK) has total liabilities worth €7.57 Million EUR (≈ $8.84 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See 8WK working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Total Liabilities of ABERA BIOSCIENCE AB (2022–2025)
Total liabilities of ABERA BIOSCIENCE AB from 2022 to 2025. This chart illustrates how ABERA BIOSCIENCE AB's total liabilities have evolved over time, based on quarterly financial data.
ABERA BIOSCIENCE AB Competitors by Total Liabilities
The table below lists competitors of ABERA BIOSCIENCE AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Biotechnology Assets S.A.
MC:BST
|
Spain | €7.01 Million |
|
Anebulo Pharmaceuticals Inc
NASDAQ:ANEB
|
USA | $1.49 Million |
|
Arcoma AB
ST:ARCOMA
|
Sweden | Skr26.30 Million |
|
Bravada Gold Corporation
V:BVA
|
Canada | CA$1.39 Million |
|
Khind Holdings Bhd
KLSE:7062
|
Malaysia | RM126.37 Million |
|
ZOONO Group Ltd
AU:ZNO
|
Australia | AU$2.53 Million |
|
StarFlex Co. Ltd
KQ:115570
|
Korea | ₩29.18 Billion |
|
Nexgram Holdings Bhd
KLSE:0096
|
Malaysia | RM62.76 Million |
Liability Composition Analysis (2022–2025)
This chart breaks down ABERA BIOSCIENCE AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see ABERA BIOSCIENCE AB (8WK) total assets.
Liquidity & Leverage Metrics
ABERA BIOSCIENCE AB Total Liabilities Ratios Explained
ABERA BIOSCIENCE AB total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.69 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.32 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.24 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ABERA BIOSCIENCE AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ABERA BIOSCIENCE AB (2022–2025)
The table below shows the annual total liabilities of ABERA BIOSCIENCE AB from 2022 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €9.28 Million ≈ $10.85 Million |
+87.59% |
| 2024-12-31 | €4.95 Million ≈ $5.78 Million |
+33.96% |
| 2023-12-31 | €3.69 Million ≈ $4.32 Million |
+32.13% |
| 2022-12-31 | €2.80 Million ≈ $3.27 Million |
-- |
About ABERA BIOSCIENCE AB
Abera Bioscience AB, a platform and vaccine development company, research, design, and develops vaccines and immunotherapies based on its proprietary vaccine delivery platform in Sweden and internationally. The company's development platform named BERA, uses for the display of antigens at the surface of outer membrane vesicles derived from genetically optimized gram-negative bacteria. Its lead va… Read more